Viiv Healthcare Ltd., of London, said the FDA approved a supplemental new drug application for dolutegravir 10 mg and 25 mg oral tablets, reducing the weight limit from at least 40 kg to at least 30 kg, in patient, ages 6 to under 12 years old, for the treatment of HIV-1.